Lung fluid may replace biopsies for cancer testing

NCT ID NCT04806412

Recruiting now Knowledge-focused Sponsor: Naestved Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at fluid from around the lungs (pleural effusion) in people with non-small cell lung cancer. Researchers want to see how often important cancer markers like PD-L1, ALK, and EGFR can be found in that fluid. They will also check if the amount of fluid tested affects the results. The goal is to learn whether this fluid can be used instead of a tissue biopsy to choose the right treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors use pleural fluid instead of tissue biopsies to guide lung cancer treatment, reducing the need for invasive procedures.
What could go wrong: This is an observational study, not a treatment trial. It only measures existing markers and does not test a new therapy, so it won't directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL EFFUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma Pleural Effusion, Malignant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT PLEURAL EFFUSION NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Næstved Sygehus, department of pulmonary medicine
RECRUITING

Næstved, Region Sjælland, 4700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.